Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.13 USD | -2.84% | -10.17% | +14.74% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.74% | 1.84B | |
+75.69% | 12.57B | |
-28.45% | 6.98B | |
+7.45% | 6.69B | |
+8.73% | 5.18B | |
-19.73% | 4.63B | |
+17.40% | 4.18B | |
-21.37% | 3.81B | |
-25.83% | 2.8B | |
-1.24% | 2B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise